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Abstract:
Technology transfer is the process of transforming research and ideas into viable commercial opportunities.
Notable examples of tech transfer include Google, artificial intelligence, life-saving vaccines, and renewable
energy technology. Universities and colleges play an important role in the technology transfer process,
ranging from brokering commercial partnerships, negotiating license agreements, and protecting
intellectual property. Valuable patents are often at stake, and as a result, universities should anticipate
litigation risks. State universities, in particular, face new and unusual challenges as a result of their status as
state entities. Under the 11th Amendment, state universities, as an arm of the state, can claim sovereign
immunity, a doctrine which provides that the government cannot be sued without its consent. However,
trends in litigation suggest that sovereign immunity protection for state universities is eroding.
This article discusses the trends in litigation that implicate sovereign immunity claims by state universities
embroiled in technology transfer disputes. The legal issues raised and discussed throughout the article are
essential for technology transfer offices and university counsel to consider when reviewing their practices,
policies, and litigation strategy. The article also provides practical recommendations on how to shift risk
away from the university.

Introduction
Under the 11th Amendment, can state
universities assert sovereign immunity to avoid being
sued by private parties in federal court for violation of
patent laws? What implications does this constitutional
tension have on technology transfer offices at state
universities? The following narrative considers these
two emerging questions through the interpretative
lens of recent litigation and relevant statutory and
constitutional provisions.
As a practical starting point, the author
provides a concise history of technology transfer in the
United States. She then surveys the laws and legislation
that govern the intersection between sovereign
immunity and technology transfer, including the 11th
Amendment and the Bayh-Dole Act. The article
subsequently examines major themes in the case law
that concern state universities’ use of sovereign
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immunity as a defense to litigation and then concludes
by discussing the implications of sovereign immunity
challenges on technology transfer offices at state
universities.
This article argues that state universities will
face an increasing burden of litigation costs and a
heightened risk of patent claims by third parties due to
an erosion of state sovereign immunity. These longterm repercussions could lead to negative downstream
effects such as chilling technology transfer activity in
the United States. Recommendations to insulate
universities from litigation costs include special
contract provisions, the use of arbitration, insurance
policies, and selecting strategic partnerships for
research discovery. The purpose of this article is to
equip technology transfer offices with an overview of
noteworthy holdings from relevant case law and
practical measures to mitigate risk.
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I. University Technology Transfer in
the United States
Historically, universities have enthusiastically
entertained entrepreneurial partnerships between
faculty members and industry players. One of the
earliest ventures blossomed in California when
chemistry professor Frederick Cottrell founded the
Research Corporation in 1912.1 Cottrell’s intentions
were to create a funding body to support scientific
research and tackle environmental concerns such as
pollution, an unanticipated product of the industrial
revolution.2 Other collaborations between the academy
and industry were born out of burgeoning growth in
the agricultural economy and a need for new
inventions (Etzkowitz, 2016). An increase in defense
research spending quickly followed on the footsteps of
World War II as completion of the Manhattan Project
and other military research campaigns became
missions of national importance (Mowery and
Ziedonis, 2000). Over the decades, federal funding in
academic research continued to flow into universities,
while the scope of investment expanded to include
engineering, physics, and biomedicine (Breznitz,
2014).
Unsurprisingly, American universities seized
the opportunity to assist faculty with patent and
licensing activities. Cottrell’s Research Corporation
was also a recognized establishment for helping faculty
with patent management.3 Globally, patent acquisition
by universities commenced as early as 1921–1922
when the University of Toronto acquired a patent on
insulin, an anabolic hormone that was discovered by
two researchers at the medical school (Bliss, 1982).
With the increase in robust research activity
and scientific discovery at major research institutions
in the middle of the 20th century, federal funding
agencies started to ask faculty members to assign their
patents to the sponsoring agency.4 At the time, the
prevailing attitude in government circles was well1

Research Corporation for Science Advancement.
Retrieved from https://rescorp.org/rcsa/history
2
Id.
3
Id.
4
American Association of University Professors.
American University Patent Policies: A Brief History.
Retrieved from
https://www.aaup.org/sites/default/files/files/ShortHistory.
pdf
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understood: what the government (and public) pays
for, it should own.5 This public policy catalyzed the
federal government to acquire approximately 30,000
patents by the 1960s.6 However, despite the good
intentions of making federally funded research
available for the public good, few inventions owned by
the government were actually being commercialized
(Feldman and Clayton, 2016).
To remedy this problem, the federal
government sought creative solutions. Understanding
that universities were well equipped to advertise and
find suitors to commercialize inventions, funding
agencies agreed to use a new type of contract that
would grant patent rights directly to universities.
Better known as the Institutional Patent Agreement
(IPA), this contract eliminated the cumbersome
process of universities having to ask the Department of
Health, Education, and Welfare (now, the HHS) to
waive title to an invention (Berman, 2008). Waiver
applications were complex, and IPAs were an efficient
way for universities to cut through procedural red tape
and initiate license agreements with industry
partners.7

II. Technology Transfer Legislation
In addition to the use of IPAs between
universities and federal agencies, three other notable
events fostered a favorable environment for university
technology transfer and intellectual property rights in
the United States. The first event occurred in 1974
when a group of research institutions founded the
Society of University Patent Administrators (now
known as the Association of University Technology
Managers: AUTM) to promote the commercialization of
academic research and to funnel inventions with high
commercial potential to the marketplace so the general
public could also reap the benefits of novel
discoveries.8 Since its founding, the AUTM has
facilitated the development of over 200 FDA-approved

5

Wisconsin Alumni Research Foundation. WARF & the
Bayh-Dole Act. Retrieved from
https://www.warf.org/about-us/history/warf-bayh-doleact/warf-bayh-dole.cmsx
6
Id.
7
Id.
8
AUTM. Mission & History. Retrieved from
https://autm.net/about-autm/mission-history
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drugs.9 The second event occurred in December 1980
with the passage of the Bayh-Dole Patent and
Trademark Amendments Act, which gave categorical
permission to universities to retain patent rights to
discoveries made with the support of federal funding
(Breznitz, 2016). The third event occurred in 1982
with the establishment of the U.S. Court of Appeals for
the Federal Circuit, which serves as the court of final
appeal for patent cases in the federal court system. 10
The Federal Circuit was established under Article III of
the Constitution and has special jurisdiction over a
variety of subject areas, including international trade,
trademarks, and patents. Since the court’s inception,
the Federal Circuit has been considered an advocate
for intellectual property rights (Mowery and Ziedonis,
2000).
Researchers Woodell and Smith (2017) argue
that the Bayh-Dole Act established the field of
university technology transfer. The U.S. Department of
Commerce, the federal agency that promotes
technology transfer commercialization, delegated
authority to the National Institute of Standards and
Technology to promulgate rule-making for the Act.11
Legislation similar to Bayh-Dole has been enacted
worldwide, including in Singapore, Russia, the United
Kingdom, and Mexico.12
The following are major provisions of the
Bayh-Dole Act, including new regulations, effective
2018 (Lee, Riemenschneider, Altmann, Sherwood,
2018).13
•

•

•

Universities may elect to retain title to
discoveries made under federally funded
research programs and must do so within two
years following disclosure of the invention if
election is made.
Universities must disclose subject inventions
to the government within two months after
the inventor discloses it to the university’s
technology transfer office.
Universities are encouraged to collaborate
with commercial entities to promote

9

Id.
United States Court of Appeals for the Federal Circuit.
Court Jurisdiction. Retrieved from
http://www.cafc.uscourts.gov/the-court/court-jurisdiction
11
National Institute for Standards and Technology.
(2020). Bayh-Dole Regulations for Federally Funded
Inventions. Retrieved from
https://www.nist.gov/tpo/bayh-dole
10
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•
•

•
•
•
•

•

•

•

commercialization of research findings that
benefit the public.
Universities are expected to file patents on
inventions they elect to own.
If a federal employee is co-inventor of the
subject invention, then the federal employee
co-inventor may file the initial patent
application, provided that the university
retains the ability to elect rights. This
determination is made by the funding agency
“at its discretion” and “in consultation with”
the university.
Universities are expected to give licensing
preference to small businesses and to those
making products in the United States.
Universities automatically grant to the
government a nonexclusive, irrevocable, paidup license to use the invention.
The government retains march-in rights under
very specific circumstances.
Universities must obtain written agreement
from employees of their responsibility to
promptly disclose subject inventions in
writing to technology transfer offices.
Universities must obtain written assignment
agreements from employees, which assign all
rights and titles to subject inventions to the
university.
Following the discovery of non-compliance of
the Bayh-Dole Act’s disclosure and election
requirements, the government has an
unlimited time to assert ownership to an
invention.
Decisions to discontinue patent prosecution
must be communicated to the government
within 60 days before the statutory deadline.

Related technology transfer legislation in the
United States includes the Stevenson-Wydler
Technology Innovation Act of 1980, which enabled
government-owned and -operated laboratories to
engage in cooperative research and development

12

AUTM. Landmark Law Helped Universities Lead the
Way. Retrieved from https://autm.net/about-techtransfer/advocacy/legislation/bayh-dole-act
13
35 U.S.C. § 200–212; AUTM. The Bayh-Dole Act: It’s
Working. Retrieved from
https://autm.net/AUTM/media/About-TechTransfer/Documents/BayhDoleTalkingPointsFINAL1193.
pdf
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agreements14; the Federal Technology Transfer Act of
1986, which allowed government inventors to patent
their technologies and receive a portion of the royalties
from commercialization15; and the America Invents Act
of 2011, which reformed the patent system to be based
on the “first inventor to file” rather than the “first to
invent.”16

11th Amendment Sovereign Immunity
The intersection between sovereign immunity
and technology transfer at state universities is a legal
tension that is frequently under debate at the U.S.
Court of Appeals for the Federal Circuit.17 Sovereign
immunity is granted to state-owned universities
because they are considered to be an arm of the state. 18
The laws that govern sovereign immunity are
found in the 11th Amendment of the U.S. Constitution
and also in common law that dates back to 1793. 19
Originating from English law, sovereign immunity is
grounded in the theory of absolute divine rights
whereby the king’s sovereign power is deemed to be
God-given and unlimited (Choi, 2018). The power of
the sovereign in medieval England effectively meant
the king could do no harm (Borchard, 1924).
The application of this legal doctrine in
American jurisprudence was discussed in Chisolm v.
Georgia, the result of which inspired Congress to enact
the 11th Amendment of the Constitution so that states
had the power to invoke immunity from suit by private
parties in federal court (Choi, 2018):
The Judicial power of the United States shall
not be construed to extend to any suit in law
or equity, commenced or prosecuted against
one of the United States by Citizens of another
State, or by Citizens or Subjects of any Foreign
State.20

14

Federal Laboratory Consortium. What is Technology
Transfer? Retrieved from https://federallabs.org/learningcenter/what-is-t2
15
15 U.S.C. §3710
16
United States Patent and Trademark Office. LeahySmith America Invents Act Implementation. Retrieved
from https://www.uspto.gov/patent/laws-andregulations/leahy-smith-america-invents-actimplementation
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In simple terms, the 11th Amendment protects
states from being forced to defend themselves against
a private party. However, immunity is not absolute,
and the Supreme Court has recognized two scenarios
where a private party can sue a state: (1) when a state
waives its sovereign immunity by consenting to the
suit; and (2) when Congress exercises its 14th
Amendment right to authorize a suit against a state. 21
While the first scenario is more straightforward in its
application, the second scenario has caused a rift in
Supreme Court judicial opinions such that recent
holdings that curtail Congress’ power to abrogate state
sovereign immunity have been deemed “judicial
activism.”22

III. Litigation Trends: University
Technology Transfer and Sovereign
Immunity Claims
Technology transfer has become a breeding
ground for litigious activity as a growing number of
lawsuits between academics, universities, and industry
reveal the web of tensions among these parties. Court
cases involving university technology transfer were
found through an online keyword search of WestLaw
in February 2020: 220 cases were discovered using the
keywords “university technology transfer” and
“patent”; 130 cases were discovered using the
keywords “university,” “patent,” and “sovereign
immunity”; and 31 cases were discovered using the
keywords “university technology transfer,” “patent,”
and “sovereign immunity.” The narrow body of case
law discussing sovereign immunity claims at state
universities points to major themes that concern
procedural issues, litigation conduct, original
jurisdiction, administrative proceedings, and
commercial activity by foreign states.

17

Infra Part III
Bd. of Regents of the Univ. of Tex. Sys v. Boston
Scientific Corp, 936 F. 3d 1365 (2019).
19
Chisolm v. Georgia, 2 U.S. 219 (1793).
20
U.S. Const. amend. XI
21
College Sav. Bank v. Florida Prepaid Postsecondary
Educ. Expense Bd., 527 U.S. 666 (1999).
22
Alden v. Maine, 527 U.S. 706 (1999); Seminole Tribe of
Fla. v. Florida, 517 U.S. 44 (1996).
18
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States Are Not Immune to Proper Transfers of
Venue
In Bd. of Regents of the Univ. of Tex. Sys v.
Boston Scientific Corp, the Board of Regents of the
University of Texas System (UT) and TissueGen, Inc.
sued Boston Scientific Corporation for patent
infringement in the Western District of Texas.23 The
patents-in-suit concerned “implantable drug-releasing
biodegradable fibers that replace the standard fibers
used in medical devices, such as implantable stents.” 24
The fibers were discovered at the University of Texas
System, and the university licensed the patents-in-suit
to TissueGen, Inc., which was founded by the UT
professor who co-discovered the technology.25
In litigating the patent infringement claim, a
procedural issue emerged. The district court
determined that venue was improper in the Western
District of Texas and transferred to the District of
Delaware.26 The University of Texas sought venue in
Texas by claiming sovereign immunity:
Venue is proper in the Western District of
Texas because UT is an arm of the State of
Texas, has the same sovereign immunity as the
State of Texas. It would offend the dignity of
the State to require it to pursue persons who
have harmed the State outside the territory of
Texas, and the State of Texas cannot be
compelled to respond to any counterclaims,
whether compulsory or not, outside its
territory due to the 11th Amendment.27
The district court rejected UT’s sovereign
immunity argument based on the longstanding rule
that venue is proper where the defendant resides or
23

Bd. of Regents of the Univ. of Tex. Sys v. Boston
Scientific Corp, 936 F.3d 1365 (2019).
24
Id.
25
Id.
26
Id.
27
Id.
28
Under the collateral order doctrine, the Federal Circuit
agreed to hear the case on appeal despite the transfer order
being interlocutory in nature. The Federal Circuit’s reason
for hearing the appeal was because the transfer order was
challenged on the basis of state sovereignty. See Puerto
Rico Aqueduct and Sewer Authority v. Metcalf & Eddy,
Inc., 506 U.S. 139 (1993). (“The Supreme Court held that
States and State entities may invoke the collateral order
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has a regular and established place of business. Since
defendant Boston Scientific Corporation was
incorporated in Delaware, the court’s decision was
logical. The district court explained that “sovereign
immunity is a shield; it is not meant to be used as a
sword … there is no claim or counterclaim against [UT]
that places it in the position of the defendant”
(emphasis added).28 On appeal, the Federal Circuit also
rejected UT’s attempt to keep the case in Texas on the
basis of sovereign immunity, holding that “the state
sovereignty principles asserted by UT do not grant it
the right to bring a patent infringement suit in an
improper venue.”29 The Federal Circuit further noted
that state sovereign immunity does not apply where
the state acts solely as a plaintiff (emphasis added).30
The outcome of the UT case has two
implications: (1) state sovereignty principles do not
give state universities the right to sue in an improper
venue; and (2) a state cannot dictate where it litigates
its property rights if the state is the sole plaintiff. Bd. of
Regents of the Univ. of Tex. Sys v. Boston Scientific Corp
also serves as a reminder that when a state or state
entity voluntarily appears in federal court, it
“voluntarily invokes the federal court’s jurisdiction”
and must abide by federal rules and procedures. 31

Waiver of Sovereign Immunity Depends on
Litigation Conduct
In Xechem Intern., Inc. v. University of Tex. M.D.
Anderson Cancer Center, the Federal Circuit considered
the issue of whether the Board of Regents of the
University of Texas System and the University of Texas
M.D. Anderson Cancer Center could assert its 11th
Amendment immunity to avoid a lawsuit in federal
court.32 The lawsuit concerned a patent correction
doctrine to immediately appeal an order denying a claim
of sovereign immunity.”)
29
Bd. of Regents of the Univ. of Tex. Sys v. Boston
Scientific Corp, 936 F.3d 1365 (2019).
30
But see A123 Systems, Inc. v. Hydro-Quebec, 626 F.3d.
1213 (2010) (The Board of Regents of a State university
could not be joined as a defendant because the State
university had not waived 11th Amendment sovereign
immunity in the lawsuit (emphasis added)).
31
Lapides v. Bd. of Regents of the Univ. Sys. of Ga., 535
U.S. 613 (2002).
32
Xechem Intern., Inc. v. University of Tex. M.D.
Anderson Cancer Center, 382 F. 3d 1324 (2004).
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claim that stemmed from a collaboration between the
university and Xechem International, a
biopharmaceutical company that was developing the
cancer drug paclitaxel.33 Xechem alleged that UT took
several actions that equated to a waiver of sovereign
immunity, such as entering into a collaborative
research agreement.34
To the contrary, the Federal Circuit held that
none of UT’s actions were a waiver of sovereign
immunity; instead, the court clarified that waiver of
sovereign immunity should be “clear, explicit, and
voluntary.”35 The court also echoed the opinion made
in Bd. of Regents of the Univ. of Tex. Sys v. Boston
Scientific Corp, which stressed the fact that a state’s
voluntary entry into federal jurisdiction serves as a
valid waiver.36
In a similar set of facts relating to patent
corrections, the Federal Circuit in Ali v. Carnegie Inst. of
Washington discussed the impact of the Bayh-Dole Act
with respect to the University of Massachusetts’
assertion of sovereign immunity.37 In particular, the
court noted that just because the patents-in-suit
resulted from federal funding through the Bayh-Dole
Act does not mean that a university “makes a clear
declaration” of its submission to federal court
jurisdiction.38 In other words, a state’s waiver must not
be implied or constructive. Furthermore, there is no
“quid pro quo arrangement” whereby a contractual
agreement between a state university and the federal
government constitutes a waiver of sovereign
immunity.39

Missouri waived its constitutional immunity by
initiating and participating in a patent interference
proceeding before the United States Patent and
Trademark Office.40 Furthermore, the court held that
the University of Missouri’s waiver at the patent
proceeding level also applied at the appellate level.
Similarly, in Regents of University of New Mexico v.
Knight, the Federal Circuit declared that the University
of New Mexico waived its sovereign immunity as to any
compulsory counterclaims when it brought a patent
ownership action against the inventors of cancer
treatment compounds.41 Waiver can also be invoked by
a defendant that voluntarily agrees to remove a case to
federal court, which was seen in Lapides v. Board of
Regents of University System of Georgia.42 By contrast, a
state university’s filing of a patent infringement action
does not waive sovereign immunity to a different suit
in a different court involving the same parties. 43
These cases stress the fact that once a state
university initiates a lawsuit in federal court, it
consents to federal court jurisdiction and waives 11th
Amendment immunity. The Supreme Court in Lapides
explained this concept further:
It would seem anomalous or inconsistent for a
State both (1) to invoke federal jurisdiction,
thereby contending that the “Judicial power of
the United States” extends to the case at hand,
and (2) to claim 11th Amendment immunity,
thereby denying that the “Judicial power of the
United States” extends to the case at hand. And
a Constitution that permitted States to follow
their litigation interests by freely asserting
both claims in the same case could generate
seriously unfair results.44

Waiver of Sovereign Immunity Through
Voluntary Pursuit of Litigation
By contrast, sovereign immunity is waived
through aggressive pursuit of litigation in federal court.
For example, in Vas-Cath, Inc. v. Curators of the Univ. of
Mo., the Federal Circuit stated that the University of

33

Id.
Id.
35
Id.
36
Bd. of Regents of the Univ. of Tex. Sys v. Boston
Scientific Corp, 936 F.3d 1365 (2019).
37
Ali v. Carnegie Inst. of Washington, 684 F. Appx. 985
(2017).
38
Id.
39
Id. at 25.
34

https://tigerprints.clemson.edu/jptrca/vol30/iss1/1

More colloquially, the Supreme Court’s
rationale to the University of Georgia was simple: “you
can’t eat your cake and have it too” (Heywood, 1546).
40

Vas-Cath, Inc. v. Curators of the Univ. of Mo., 473 F.
3d 1376 (2007).
41
Regents of University of New Mexico v. Knight, 321 F.
3d 1111 (2003).
42
Lapides v. Bd. of Regents of the Univ. Sys. of Ga., 535
U.S. 613 (2002).
43
Tegic Communications Corp. v. Board of Regents of
University of Texas System, 458 F. 3d 1335 (2006).
44
Lapides v. Board of Regents of University System of
Georgia, 535 U.S. 613 (2002).
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The Supreme Court Has Jurisdiction Over
Suits Between State Universities

Sovereign Immunity Does Not Bar Inter
Partes Review

The majority of cases discussing technology
transfer at state universities and sovereign immunity
involve a single state university and a private actor.
However, in University of Utah v. Max-PlanckGesellschaft Zur Forderung Der Wissenschaften E.V., a
state university brought a patent correction claim
against another state university.45 The dispute
concerned two professors who had presented about
RNA interference issues at the same professional
conferences and were familiar with one another’s
work. When the University of Massachusetts’s
professor filed for and was granted a patent, the
University of Utah professor sued for a correction of
patent ownership, claiming she was the rightful owner.
Since the dispute arose between two state universities,
the University of Massachusetts argued that the
Supreme Court had jurisdiction over the dispute under
the Constitution’s Original Jurisdiction clause.46
The Federal Circuit held that the Supreme
Court did not have exclusive jurisdiction over the
patent claim between two state universities. 47 The
reasons provided by the court were complex but
generally referred to the fact that (1) the University of
Massachusetts was not an indispensable or real party
of interest; and (2) the State has no core sovereign
interest in inventorship.48 The Federal Circuit also
reminded the universities that states do not enjoy
sovereign immunity from suits brought by other
states.49 The case was filed before the Supreme Court
yet denied in 2014, meaning that the lower court
decision stands. Interestingly, this case raises the
question as to whether a state could ever have a
sovereign interest in a patent invention.

Whether or not sovereign immunity can be
invoked in an inter partes review (IPR) proceeding was
discussed in Regents of the University of Minnesota v.
LSI Corporation.50 Established in 2012, inter partes
review is a trial proceeding conducted at the USPTO
Patent Trial and Appeal Board to review the
patentability of one or more claims in a patent. 51 IPRs
were created to address the public’s confidence and
trust in the patent system by giving patent challengers
an opportunity to purge bad patents through a reexamination forum (Janis, 1997).52 In this case, the
University of Minnesota brought a patent infringement
action against a group of alleged infringers of the
university’s semiconductor chip patents.53 In response,
the alleged infringers subsequently filed petitions for
inter partes review, but the University of Minnesota
moved to dismiss the IPR proceedings based on
sovereign immunity. The university argued that
sovereign immunity applies to Article III proceedings
and therefore should also apply to IPR proceedings.
However, the Federal Circuit disagreed with
the University of Minnesota, concluding that sovereign
immunity does not apply to IPR proceedings because
an IPR is “more like an agency enforcement action
rather than a civil suit brought by a private party.”54
Furthermore, the court noted that the Federal Rules of
Civil Procedure do not apply in IPR proceedings and
that petitioners do not have to be present for a final
decision to be rendered by the Patent Trial and Appeal
Board.55 The university filed suit before the Supreme

45

50

University of Utah v. Max-Planck-Gesellschaft Zur
Forderung Der Wissenschaften E.V., 734 F. 3d 1315
(2013).
46
U.S. Const. art. III, § 2, cl. 2 (“In all Cases … in which
a State shall be a Party, the [S]upreme Court shall have
original Jurisdiction.”)
47
University of Utah v. Max-Planck-Gesellschaft Zur
Forderung Der Wissenschaften E.V., 734 F. 3d 1315
(2013).
48
Id.
49
University of Utah v. Max-Planck-Gesellschaft Zur
Forderung Der Wissenschaften E.V., 734 F. 3d 1315
(2013);
Texas v. New Mexico, 482 U.S. 124 (1987).
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Regents of the University of Minnesota v. LSI
Corporation, 926 F. 3d 1327 (2019).
51
United States Patent and Trademark Office. Inter Partes
Review. Retrieved from https://www.uspto.gov/patentsapplication-process/appealing-patent-decisions/trials/interpartes-review
52
See S. Rep. No. 96–617, at 2–3, 14S. Rep. No. 96–617,
at 2–3, 14 (1980); H.R. Rep. No. 96–1307, pt. 1, at 3
(1980) (expressing concern as to the lack of confidence in
the patent system).
53
Regents of the University of Minnesota v. LSI
Corporation, 926 F. 3d 1327 (2019).
54
Id.
55
Id.
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Court, but this request was denied in 2020, leaving the
Federal Circuit’s decision unchanged.56
Several amici briefs, or briefs written by
parties with a strong interest in the case, were filed by
other state universities, which highlighted the
potential harm that the Federal Circuit’s decision in
Regents of the University of Minnesota would cause.57
One of the major ramifications of the decision was both
“practical and economic.”58 State universities would be
forced to defend valuable patents in an increasing
number of IPR proceedings, which cost roughly half a
million dollars on average per proceeding.59 Another
dire consequence of this decision is the chipping away
of the structural division of power between states and
the federal government that is guaranteed by the
Constitution.

state is presumptively immune from the jurisdiction of
United States courts,”62 unless a foreign state “engages
in commercial activity … in the United States.”63 The
Federal Circuit further explained that (1) obtaining U.S.
patents and (2) enforcing patents through litigation or
licensing activity are commercial activities for the
purposes of determining jurisdiction under the FSIA.64
This case is important for foreign universities who
actively pursue commercial interests in the United
States.

IV. Implications for Technology
Transfer Programs at State Universities

In Genetic Veterinary Sciences, Inc. v. LABOKLIN
GmbH & Co KG, the Federal Circuit also addressed
whether foreign universities can assert sovereign
immunity in the U.S. federal judiciary.60 In the lower
court proceedings, the University of Bern and
LABOKLIN asserted a patent infringement claim
against an American company (PPG) for using the
university’s patent in tests that detect genetic diseases
in dogs.61 In response, PPG asked the district court
whether the patents-in-suit were ineligible for
protection under § 101 for failing to claim patenteligible subject matter. When the district court
determined that the patents were ineligible, the
university and LABOKLIN appealed the decision,
stating that the U.S. district court lacked personal and
subject matter jurisdiction over the university because
of sovereign immunity.
Pursuant to the Foreign Sovereign Immunities
Act (FSIA), the Federal Circuit explained that “a foreign

Over the past several decades, federally
funded technology transfer programs have fostered
innovation and delivered a pipeline of novel,
potentially life-changing discoveries to the public. For
example, between 1969 and 2012, the USPTO issued
over 75,000 patents to American universities (USPTO,
2020). However, case law reveals that state
universities may be dragged into more legal disputes
despite their cry for sovereign immunity. This trend in
litigation activity has three important implications for
American innovation.
First, state universities will suffer economic
headwinds due to a rise in litigation costs from
pursuing and defending patent claims. The holding in
Regents of the University of Minnesota v. LSI Corporation
is particularly worrisome given that the decision flings
the door wide open for state universities to be hauled
into new types of litigation proceedings, such as inter
partes review. The problem with this type of tribunal is
that a single patent or patent portfolio can be subjected
to an unlimited number of administrative reviews by
an unlimited number of petitioners.65 Furthermore, the
costs of defending these claims would dramatically

56

61

Foreign Sovereign Immunities Act

Supreme Court of the United States Blog. Retrieved
from https://www.scotusblog.com/case-files/cases/regentsof-the-university-of-minnesota-v-lsi-corporation/
57
Id.
58
Regents of the University of Minnesota v. LSI
Corporation. (2019). Petition for Writ. Retrieved from
https://www.supremecourt.gov/DocketPDF/19/19337/115569/20190912124127177_UMN%20Petition%20a
nd%20Appendix.pdf
59
Id.
60
Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH
& Co KG, 933 F. 3d 1302 (2019).

https://tigerprints.clemson.edu/jptrca/vol30/iss1/1

Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH
& Co KG, 314 F. Supp 3d 727 (May, 2018).
62
Saudi Arabia v. Nelson, 507 U.S. 349 (1993).
63
28 U.S.C. § 1605(a)(2).
64
Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH
& Co KG, 933 F. 3d 1302 (2019); Intel Corp. v.
Commonwealth Sci. & Indus. Research Org., 455 F.3d
1364 (2006).
65
Regents of the University of Minnesota v. LSI
Corporation. (2019). Petition for Writ. Retrieved from
https://www.supremecourt.gov/DocketPDF/19/19-
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constrain the budgets of state universities, which
depend on revenues from intellectual property
development for reinvestment in research and public
education.66 Also, the cost to defend more legal
disputes would prune the resources that state
universities use to prosecute infringers of valuable
university-owned patents.67
The second implication is an overall negative
impact on the social good due to a constricted
downstream flow of new patent filings. With new
litigation risks on the horizon, state universities may
avoid filing patent applications for speculative
innovations.68 This behavior not only deprives state
universities of prospective revenue from patenting and
licensing activities, it also stunts innovation as fewer
discoveries trickle into the market. The long-term
effect of overcaution by university technology transfer
programs could mean fewer groundbreaking
developments of the magnitude that have led to robust
job growth and the creation of entire industries. If such
effects come to fruition, the United States’ standing in
the global innovation economy could eventually
decline. The global shift in dynamics has already
started to surface as China became the worldwide
leader in patent filings in 2019 (Hosokawa, 2020). To
further illustrate the probability of decreased
technology transfer, an empirical study (Hvide and
Jones, 2018) conducted in Norway revealed that a
formal policy shift in rights from researcher to the
university led to an approximate 50 percent drop in
the rate of startups by university researchers between
2000 - 2007, highlighting the sensitivity of the
relationship between rights management and
entrepreneurial activity.
A third implication is that the decisions
handed down by the Federal Circuit are a direct affront
to the states’ right of sovereign immunity. By allowing

states and state entities to be sued in administrative
proceedings without its consent, federal courts are
tarnishing the sovereign dignity of states and
promoting an imbalance of powers within the legal
system.
This tension between federal and state power,
a division that forms the basis of American federalism,
is still hotly contested among Supreme Court justices.
The debate roars in the dissents of cases such as Alden
v. Maine, Kimel v. Florida Bd. of Regents, and Seminole
Tribe.69 For example, the dissent in Alden points out
that the right to sovereign immunity by states was
curtailed when the Constitution was ratified in 1788. 70
Likewise, the dissent in Alden argues that Congress has
the power to exercise its Article I power to abrogate
state sovereign immunity.71 By contrast, the majority
in Alden writes that the 10th Amendment, rather than
the 11th, gives states the right to be immune from all
suits “whether the court be state and federal, and
whether the cause of action arises under state or
federal law.”72 Under the majority’s reasoning, a state’s
reliance on the 11th Amendment is unnecessary.73
An unintended consequence of the developing
body of case law discussing state sovereign immunity
and technology transfer is that state sovereign
immunity is eroding, despite the Supreme Court’s
majority holdings that have advocated for state rights.

337/115569/20190912124127177_UMN%20Petition%20a
nd%20Appendix.pdf
66
Regents of the University of Minnesota v. LSI
Corporation. (2019). Brief of the Association of Public
and Land-Grant Universities as Amicus Curiae in Support
of Petitioner. Retreived from
https://www.supremecourt.gov/DocketPDF/19/19337/118860/20191011163438730_2019-1011%20PDFA%20APLU%20Cert%20Stage%20Amicus%
20Brief%20-%20for%20Printer.pdf
67
Id.
68
Regents of the University of Minnesota v. LSI
Corporation. (2019). Brief of Twelve State University

Systems as Amici Curiae in Support of Petitioner.
Retrieved from
https://www.supremecourt.gov/DocketPDF/19/19337/119034/20191015154508370_19337%20Amicus%20Brief.pdf
69
Alden v. Maine, 527 U.S. 706 (1999); Kimel v. Florida
Bd. of Regents, 528 U.S. 62 (2000); Seminole Tribe of Fla.
v. Florida, 517 U.S. 44 (1996).
70
Alden v. Maine, 527 U.S. 706 (1999).
71
Id.
72
Id.
73
Id.
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V. Conclusion
Protecting the culture of innovation within
academia requires technology transfer offices to
balance protection of intellectual property interests
with prudent investment of federal funding into fruitful
research and novel discoveries. Technology transfer
programs at state universities have the additional
burden of reserving adequate funds from state budgets
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to fend off patent trolls and other litigious creatures.
Understanding the principles of when state
universities can invoke sovereign immunity may save
these institutions from unnecessary costs.
Provided below is a summary of factors that
determine when sovereign immunity is waived and
when sovereign immunity is invoked by a state
university. Although not exclusive given the everexpanding body of case law, this outline serves as a
practical resource for technology transfer offices at
state universities to consult.

Sovereign Immunity Is NOT Waived:
•
•
•

•
•
•
•
•
•
•

Entering into a collaborative research
agreement
Contracting with a private party in a license
agreement for purposes of commercial gain
Entering into an arrangement controlled by
federal law, such as patent licensing and
royalties activity
The act of university employees applying for
patents
Seeking the legal benefits of the USPTO
Filing patent applications with a federal
agency
Calling for a correction to a patent
Invoking the authority of the USPTO to enforce
patent rights
Obtaining federal funding through the BayhDole Act
Waiving sovereign immunity in one case while
a different suit in a different court is
concurrently being tried with the same parties

Sovereign Immunity IS Waived:

•

•
•

Below are recommendations on how
technology transfer programs can shift risk away from
the university:
•
•
•
•

•
•

•
•
•
•
•

•
•
•
•

Sovereign immunity should be clear, explicit,
and voluntary.
A state’s voluntary entry into federal
jurisdiction is a valid waiver.
Initiating a patent interference proceeding
before the USPTO is a valid waiver.
Sovereign immunity as to compulsory
counterclaims is also waived if a lawsuit is
initiated by the state university.

https://tigerprints.clemson.edu/jptrca/vol30/iss1/1

If the state university (as defendant) agrees to
remove a case to federal court, sovereign
immunity is waived.
Sovereign immunity does not apply in inter
partes review (IPR) proceedings.
Foreign universities waive sovereign
immunity if they have obtained a U.S. patent,
have been enforcing patents through litigation,
or have been engaging in commercial activity
in the United States.

Draft licensing agreements such that licensees
assume a share of the litigation risk.
Consider strategic joint ventures with wellfunded entities.
Assess patent litigation risk through a
comprehensive early-stage patent search.
Research competitors, marketing materials,
industry practices, the international
marketplace, technical publications, press
releases, and shareholder announcements.
Consider the impact from a potential default
judgment resulting from failure to participate
in a voluntary inter partes review proceeding.
Invest in insurance for prospective patent
disputes and demand insurance policy
language that accurately and adequately
provides relief.
Develop a risk management strategy.
Consider litigation financing to fund highstakes patent suits.
Pursue alternate forms of dispute resolution,
such as mediation and arbitration, to mitigate
the expense of litigation.
Consider pursuing litigation in international
venues where laws are more favorable.
Eliminate co-invention scenarios where
government employees are implicated in
collaborative research.

10

Gambill: Sovereign Immunity Issues for Tech Transfer Programs

References
Etzkowitz, H. (2016). The evolution of technology
transfer, in University Technology Transfer: The
globalization of academic innovation. New York, NY:
Routledge.
Mowery, D. C. and Ziedonis, A. A. (2000) Numbers,
Quality, and Entry: How Has the Bayh-Dole Act Affected
U.S. University Patenting and Licensing? in Innovation
Policy and the Economy, Vol. 1, Chicago, IL: University
of Chicago Press.
Breznitz, S. (2014) Factors Affecting University
Technology Transfer, in The Fountain of Knowledge: The
Role of Universities in Economic Development. Stanford,
CA: Stanford University Press.
Bliss, M. (1982). The Discovery of Insulin. Chicago, IL:
University of Chicago Press.
Feldman, M. and Clayton, P. (2016). The American
experience in university technology transfer, in
University Technology Transfer: The globalization of
academic innovation. New York, NY: Routledge.
Berman, E. P. (2008). Why Did Universities Start
Patenting? Institution-Building and the Road to the
Bayh-Dole Act. Social Studies of Science, 38(6).
Breznitz, S. (2016). The globalization of academic
innovation in University Technology Transfer: The
globalization of academic innovation. New York: NY:
Routledge.
Woodell, J.K. and Smith, T. L. (2017). Technology
Transfer for All the Right Reasons. Technology and
Innovation, 18, 295-304.

Published by TigerPrints, 2020

Choi, J. (2018). Our Sovereignty, Patently: A Historical
Perspective on Fitting Patent Rights with State and
Tribal Sovereign Immunity. Georgetown Journal of Law
& Public Policy.
Borchard, E. (1924). Government Liability in Tort. Yale
Law Journal, 34(1), 2.
Heywood, J. (1546). Bartlett’s Familiar Quotations
(16th ed.).
Janis, M.D. (1997). Rethinking Reexamination: Toward
a Viable Administrative Revocation System for U.S.
Patent Law. Harvard Journal of Law & Technology,
11(1), 9–10.
U.S Patent and Trademark Office (2020). U.S. Colleges
and Universities-Utility Patent Grants, Calendar Years
1969-2012. Retrieved from
ttps://www.uspto.gov/web/offices/ac/ido/oeip/taf/u
niv/org_gr/all_univ_ag.htm
Hvide, H.K. and Jones, B. F. (2018). University
Innovation and the Professor’s Privilege. American
Economic Review, 108(7), 1860–98.
Lee, R.D., Riemenschneider, K.O, Altmann, C.R.,
Sherwood, A.J., (2018). Amendments to Bayh-Dole Act
Regulations Tweak Rights to Inventions Made Using
Federal Assistance. Retrieved from
https://www.arnoldporter.com/en/perspectives/publ
ications/2018/05/amendments-to-bayh-dole-actregulations-tweak
Hosokawa, R. (2020). China overtakes US as leader in
international patent filings. Nikkei Asia Review.
Retrieved from
https://asia.nikkei.com/Business/Technology/Chinaovertakes-US-as-leader-in-international-patent-filings

11

